JP4854899B2 - カルバペネム系抗生物質組成物の処方方法 - Google Patents

カルバペネム系抗生物質組成物の処方方法 Download PDF

Info

Publication number
JP4854899B2
JP4854899B2 JP2001534377A JP2001534377A JP4854899B2 JP 4854899 B2 JP4854899 B2 JP 4854899B2 JP 2001534377 A JP2001534377 A JP 2001534377A JP 2001534377 A JP2001534377 A JP 2001534377A JP 4854899 B2 JP4854899 B2 JP 4854899B2
Authority
JP
Japan
Prior art keywords
temperature
solution
carbonate
lactam
carbapenem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001534377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514779A (ja
JP2003514779A5 (enExample
Inventor
アル−デイネイ，アンソニー
ハンク，ウイリアム・エイ
イリグ，キヤスリーン・ジエイ
カナイキ，アナンド
パテル，ハイレン
レイノルズ，スコツト・デイー
ツイノンチドウス，ステリオス・シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2003514779A publication Critical patent/JP2003514779A/ja
Publication of JP2003514779A5 publication Critical patent/JP2003514779A5/ja
Application granted granted Critical
Publication of JP4854899B2 publication Critical patent/JP4854899B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2001534377A 1999-10-29 2000-10-27 カルバペネム系抗生物質組成物の処方方法 Expired - Lifetime JP4854899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16248299P 1999-10-29 1999-10-29
US60/162,482 1999-10-29
PCT/US2000/029869 WO2001032172A1 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions

Publications (3)

Publication Number Publication Date
JP2003514779A JP2003514779A (ja) 2003-04-22
JP2003514779A5 JP2003514779A5 (enExample) 2011-04-14
JP4854899B2 true JP4854899B2 (ja) 2012-01-18

Family

ID=22585803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534377A Expired - Lifetime JP4854899B2 (ja) 1999-10-29 2000-10-27 カルバペネム系抗生物質組成物の処方方法

Country Status (8)

Country Link
EP (1) EP1244444B1 (enExample)
JP (1) JP4854899B2 (enExample)
AT (1) ATE285770T1 (enExample)
AU (1) AU770165B2 (enExample)
CA (1) CA2388163C (enExample)
DE (1) DE60017194T2 (enExample)
ES (1) ES2234689T3 (enExample)
WO (1) WO2001032172A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548492B1 (en) * 1999-10-29 2003-04-15 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
JP2005522422A (ja) * 2002-02-01 2005-07-28 シモダ、バイオテック（プロプライエタリー）リミテッド 医薬組成物
EP2505191A1 (en) * 2008-06-11 2012-10-03 Ranbaxy Laboratories Limited Lyophilized Carbapenem antibiotic composition
US8691803B2 (en) 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
US10016383B2 (en) 2013-05-07 2018-07-10 Mcmaster University Inhibitors of metallo-β-lactamase-enzymes
KR101587420B1 (ko) * 2014-08-20 2016-01-22 주식회사 대웅제약 에르타페넴-함유 동결건조제제의 제조방법
KR20170014842A (ko) 2015-07-31 2017-02-08 주식회사 대웅제약 개선된 에르타페넴 주사제의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018800A1 (en) * 1996-10-28 1998-05-07 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
WO1998057973A1 (en) * 1997-06-16 1998-12-23 Merck & Co., Inc. Stabilized carbapenem intermediates and synthetic use
US5952323A (en) * 1996-05-28 1999-09-14 Merck & Co., Inc. Carbapenem antibiotic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970281B1 (en) * 1996-05-28 2002-04-30 Merck & Co Inc Carbapenem antibiotic, composition and method of preparation
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952323A (en) * 1996-05-28 1999-09-14 Merck & Co., Inc. Carbapenem antibiotic
WO1998018800A1 (en) * 1996-10-28 1998-05-07 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
WO1998057973A1 (en) * 1997-06-16 1998-12-23 Merck & Co., Inc. Stabilized carbapenem intermediates and synthetic use

Also Published As

Publication number Publication date
ATE285770T1 (de) 2005-01-15
WO2001032172A1 (en) 2001-05-10
CA2388163A1 (en) 2001-05-10
JP2003514779A (ja) 2003-04-22
EP1244444B1 (en) 2004-12-29
CA2388163C (en) 2009-08-25
AU1245601A (en) 2001-05-14
DE60017194T2 (de) 2005-12-22
DE60017194D1 (de) 2005-02-03
EP1244444A1 (en) 2002-10-02
AU770165B2 (en) 2004-02-12
ES2234689T3 (es) 2005-07-01
EP1244444A4 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
JP6239167B2 (ja) リポペプチド組成物および関連する方法
RU2322980C2 (ru) Композиции, содержащие пиперациллин и тазобактам, применимые для инъекции
US6548492B1 (en) Process for formulation of carbapenem antibiotic compositions
JP5004964B2 (ja) 再溶解後の改善された安定性を有する凍結乾燥ピペラシリンナトリウムの調製方法
US20040204372A1 (en) Compositions containing pipercillin and tazobactam sodium useful for injection
AU2001261079A1 (en) Process for formulation of antibiotic compounds
CA1056729A (en) Injectable amoxycillin composition
JP4854899B2 (ja) カルバペネム系抗生物質組成物の処方方法
JP2003514779A5 (enExample)
US6486150B2 (en) Process for formulation of antibiotic compounds
CN103127097B (zh) 厄他培南的药物组合物
JP6487028B2 (ja) エルタペネム含有凍結乾燥製剤の製造方法
EP0278243B1 (en) Medical preparation comprising aspoxicillin, a method for its preparation, and the use of such a preparation for the manufacture of a medicament
WO2012066492A1 (en) Processes for the preparation of carbapenem antibiotic composition
JP2004269401A (ja) 凍結乾燥製剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110216

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111018

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111026

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141104

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4854899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141104

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term